**Summary**
EMV Capital PLC, a deep tech, life sciences, and sustainability venture capital investment group, released a trading and portfolio update for the year ended 31 December 2025. The company reported strong operational and portfolio performance, with total Assets Under Management (AUM) exceeding £100 million. Key highlights include
1. **Operational Growth**Scaling of the core venture capital platform, increased AUM, and strengthened revenue streams.
2. **Portfolio Support**Syndicated fundraisings totaling £12.0 million across 14 portfolio companies, and advancement of the Venture Building program, generating £10.4 million in fair value creation.
3. **Strategic Acquisitions**Acquisition of XF-73 intellectual property and clinical assets from Destiny Pharma Limited, forming AMR Bio Limited.
4. **Financial Performance**Group revenue grew by 16% to £2.8 million, driven by higher corporate finance fees and increased fundraising activity. EMV Capital core revenue increased to £3.2 million, covering a significant portion of operating costs.
5. **Portfolio Highlights**Notable progress in portfolio companies like Wanda Health, EpiBone, AMR Bio, Deeptech Recycling Technologies, Sofant Technologies, Q-Bot, and Martlet Capital, with successful fundraisings, strategic milestones, and value creation.
Despite challenging market conditions, EMV Capital remains focused on disciplined capital deployment, proactive portfolio management, and scaling its platforms. The company is well-positioned to navigate market uncertainty and benefit from a recovery in capital markets.